This review, in addition to updating the growing list of type 1 diabetes–relevant gene therapies, offers an outline of short-term objectives that can readily be met to move, at least, adenoviral and adeno-associated viral-based protocols into the clinic, first as a means of facilitating islet allografts as well as platforms with which to introduce immunoregulatory transgenes. A wide array of genes have been tested to restore insulin production, to drive the differentiation of insulin-producing progenitors, and to confer immunosuppression in an antigen- and tissue-restricted manner.
D'ANNEO A, ROOD P, BOTTINO R, BALAMURUGAN AN, HE J, GIANNOUKAKIS N (2006). Gene therapy for type 1 diabetes: is it ready for the clinic?. IMMUNOLOGIC RESEARCH, 36, 83-89 [10.1385/IR:36:1:83].
Gene therapy for type 1 diabetes: is it ready for the clinic?
D'ANNEO, Antonella;
2006-01-01
Abstract
This review, in addition to updating the growing list of type 1 diabetes–relevant gene therapies, offers an outline of short-term objectives that can readily be met to move, at least, adenoviral and adeno-associated viral-based protocols into the clinic, first as a means of facilitating islet allografts as well as platforms with which to introduce immunoregulatory transgenes. A wide array of genes have been tested to restore insulin production, to drive the differentiation of insulin-producing progenitors, and to confer immunosuppression in an antigen- and tissue-restricted manner.
| File | Dimensione | Formato | |
|---|---|---|---|
|
2006 D'Anneo et al Immunol Res.pdf
accesso aperto
Descrizione: 2006 D'Anneo et al Immunol Res
Dimensione
472.08 kB
Formato
Adobe PDF
|
472.08 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
